secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001193125-22-057861
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q4 net loss $52.7M, FY2021 net loss $187.1M; RAS pipeline advances
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $577.1M at Dec 31, 2021 vs $440.7M at Dec 31, 2020.
- Total revenue $9.5M Q4 2021 vs $8.8M Q4 2020; FY2021 $29.4M vs $43.0M FY2020 (incl. $8.5M non-cash adjustment).
- Net loss $52.7M Q4 2021 vs $34.2M Q4 2020; FY2021 $187.1M vs $108.2M FY2020.
- Full year 2022 GAAP net loss guidance $260M-$290M; stock-based comp $35M-$40M.
- RMC-4630+sotorasib Phase 2 first patient dosed; IND plans: RMC-6236 & RMC-6291 H1 2022, RMC-9805 H1 2023, RMC-8839 H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522057861/0001193125-22-057861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522057861/d214686d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-057861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer